Stephen Forman - Mar 31, 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Stock symbol
LIXT
Transactions as of
Mar 31, 2025
Transactions value $
$0
Form type
4
Date filed
4/2/2025, 10:36 AM
Previous filing
Jan 22, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +5.85K $0.00 5.85K Mar 31, 2025 Common 5.85K $1.21 Direct F1
holding LIXT Options to Purchase Common Stock 3.03K Mar 31, 2025 Common 3.03K $2.33 Direct
holding LIXT Options to Purchase Common Stock 3.86K Mar 31, 2025 Common 3.86K $1.30 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $2.37 Direct
holding LIXT Options to Purchase Common Stock 3.02K Mar 31, 2025 Common 3.02K $2.37 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $5.88 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K Mar 31, 2025 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K Mar 31, 2025 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 2.11K Mar 31, 2025 Common 2.11K $57.00 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 833 Mar 31, 2025 Common 833 $9.00 Direct
holding LIXT Options to Purchase Common Stock 833 Mar 31, 2025 Common 833 $66.00 Direct
holding LIXT Warrants to Purchase Common Stock 1.67K Mar 31, 2025 Common 1.67K $60.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 5,851 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.